Vaccine: X最新文献

{"title":"Cost of introducing human papillomavirus vaccination into Nigeria's expanded program on immunization: Lessons from two Nigerian states","authors":"Ismail Ndalami Salihu ,&nbsp;Shafik Sekitto ,&nbsp;Benjamin Mari Aya ,&nbsp;Ahmed Rufai Garba ,&nbsp;Sulaiman Etamesor ,&nbsp;Binta Aduke Ismail ,&nbsp;Adaugo Nneoma Chidubem ,&nbsp;Mohammed Yahaya ,&nbsp;Donald S. Shepard","doi":"10.1016/j.jvacx.2026.100801","DOIUrl":"10.1016/j.jvacx.2026.100801","url":null,"abstract":"<div><h3>Introduction</h3><div>In 2023, Nigeria incorporated the Human papillomavirus (HPV) vaccine into its Expanded Program on Immunization to reduce the burden of HPV-related cervical cancer. This study estimated the financial costs and explored implementation experiences of HPV vaccine introduction in Nigeria, focusing on Bayelsa (southern) and Taraba (northern) states – two geographically challenging areas.</div></div><div><h3>Methods</h3><div>A mixed-methods approach was used. Quantitative costing captured vaccine and operational expenditures using program documents, including the approved vaccine introduction grant and activity reports, reflecting actual 2023 costs. Costing was conducted from the provider perspective, with all costs reported in 2023 US dollars. Key informant interviews provided additional insights to contextualize quantitative findings.</div></div><div><h3>Results</h3><div>Both states achieved high coverage (Bayelsa, 74%; Taraba, 78%), approaching the ambitious 80% national target. The total financial cost per fully vaccinated girl was similar – $5.76 (Bayelsa) and $5.75 (Taraba). Vaccine accounted for $4.73 (≈82%) per girl, while operational costs were $1.04 and $1.02 in the respective states. Operational costs were mainly driven by transportation, logistics and data tool costs (Bayelsa: 40.74%; Taraba: 42.20%). Service delivery (Bayelsa, 22.2%; Taraba, 22.4%), and advocacy, communication, and social mobilization (ACSM) costs (Bayelsa, 16.42%; Taraba, 16.70%) were also notable cost drivers. Qualitative insights from key stakeholders highlighted strong leadership, coordination, ACSM and partners collaboration, as critical in achieving high coverage, while need for context-specific resource allocation was evident due to difficult terrains.</div></div><div><h3>Conclusion</h3><div>HPV vaccine introduction in Bayelsa and Taraba demonstrated that an initial intensive campaign strategy, supported by strong community engagement via ACSM and partners collaboration, can rapidly achieve high coverage in hard-to-reach terrains. Vaccine procurement remains the largest cost, highlighting the need for sustainable financing. Terrain-related differences emphasize the need for context-specific resource allocation. This experience provides a practical model for other low– and middle–income countries planning nationwide HPV vaccine scale-up and health-system strengthening.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"29 ","pages":"Article 100801"},"PeriodicalIF":2.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147420333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human papillomavirus vaccine knowledge, awareness, attitudes, beliefs, and behaviors among community college students: A scoping review","authors":"Eric Pittman ,&nbsp;Sai Veeramachaneni ,&nbsp;Brady Suttles ,&nbsp;Dylan Barker ,&nbsp;Manjot Nagra ,&nbsp;M. Allison Ford ,&nbsp;Minsoo Kang ,&nbsp;Hannah Allen ,&nbsp;Marie Barnard","doi":"10.1016/j.jvacx.2026.100798","DOIUrl":"10.1016/j.jvacx.2026.100798","url":null,"abstract":"<div><div>Human Papillomavirus (HPV) is the most prevalent sexually transmitted infection in the United States. Although an effective vaccine for preventing HPV-associated dis-eases has been available for nearly two decades in the United States, uptake among adolescents has lagged behind expectations. This gap in adolescent protection places those entering college at increased risk for developing complications from HPV infection. With catch-up vaccination being recommended for everyone not fully vaccinated through age 26, college students represent an ideal population to target for catch-up vaccination. Despite comprising a significant segment of the undergraduate population in the United States, community college students have been largely overlooked in HPV-related research, which has primarily focused on students attending four-year institutions. This review describes the current literature on HPV-related constructs of knowledge, awareness, attitudes, beliefs, and behaviors among community college students in the United States. An initial search identified 3783 articles for review with 14 articles meeting inclusion criteria. A majority of the studies included were cross-sectional surveys comprised of undergraduates attending various types of institutions. Among those fourteen studies, disaggregated outcome data for community college students was identifiable in 57% of the studies. Only five studies focused on community college students. While all included studies examined HPV vaccination behaviors, significant gaps were noted around HPV knowledge, awareness, attitudes, and beliefs. Further, few studies compared HPV-related data from community college students to other types of college students. Need exists to further understand HPV-related information among community college students to increase catch-up vaccinations among this vulnerable population.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"29 ","pages":"Article 100798"},"PeriodicalIF":2.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147421632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The journey towards mRNA vaccine technology transfer: From knowledge to implementation","authors":"Caryn Fenner ,&nbsp;António Lima Grilo ,&nbsp;Ike James ,&nbsp;Claudia Nannei ,&nbsp;Martin Friede ,&nbsp;Charles Gore ,&nbsp;Marie Paule Kieny ,&nbsp;Petro Terblanche","doi":"10.1016/j.jvacx.2026.100787","DOIUrl":"10.1016/j.jvacx.2026.100787","url":null,"abstract":"<div><div>Coronavirus disease 2019 (COVID-19) vaccines were less accessible in low- and middle-income countries (LMICs) than in high-income countries during the pandemic. As a result, vaccine distribution initiatives such as COVID-19 Vaccines Global Access and the African Union's African Vaccine Acquisition Trust were established to guarantee equitable access to COVID-19 vaccines in LMICs. Yet these initiatives alone did not suffice to reverse the inequity.</div><div>As a response, the World Health Organization and the Medicines Patent Pool launched the messenger RNA (mRNA) Technology Transfer Programme in June 2021 to support sustainable mRNA vaccine production in LMICs. Afrigen Biologics and Vaccines (Afrigen) in Cape Town, South Africa became the heart of a global collaborative network embarking on a challenging yet innovative journey to develop its first mRNA vaccine, AfriVac 2121, amidst a global pandemic. The World Health Organization also selected 15 manufacturing partners from LMICs in Africa, Europe, South America, and Asia to join the program and receive the mRNA vaccine manufacturing platform.</div><div>In this article, we outline the establishment of the programme, its technology transfer strategy, and the progress made in equipping partners with the capacity to implement mRNA technology. We describe the development of the manufacturing platform and pre-clinical validation, and we reflect on the key successes and challenges encountered along the way.</div><div>Despite the obstacles, the program has laid the groundwork for a globally distributed, locally driven mRNA vaccine manufacturing ecosystem, and fully equipped the main hub at Afrigen for mRNA vaccine development and manufacturing. Our work underscores the imperative need for sustained investment in technology access, global collaboration, local expertise and infrastructure to ensure equitable access to life-saving vaccines.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"29 ","pages":"Article 100787"},"PeriodicalIF":2.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146038876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-emergency use authorization active safety surveillance study of the Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine in the Veterans Affairs health system: Findings from a three-year, comprehensive safety assessment program","authors":"Kofi Asomaning ,&nbsp;Mei Sheng Duh ,&nbsp;Maral DerSarkissian ,&nbsp;Cynthia de Luise ,&nbsp;Catherine Nguyen ,&nbsp;Mu Cheng ,&nbsp;Angela Lax ,&nbsp;Tracy Guo ,&nbsp;Marianne Cunnington ,&nbsp;Pierre Cremieux ,&nbsp;Yinong Young-Xu ,&nbsp;Caroline Korves ,&nbsp;Jurandir Dalle Lucca","doi":"10.1016/j.jvacx.2026.100791","DOIUrl":"10.1016/j.jvacx.2026.100791","url":null,"abstract":"<div><h3>Background</h3><div>This non-interventional, active safety surveillance study conducted signal detection/evaluation analyses for the primary series, monovalent booster doses, and Omicron BA.4/BA.5-adapted bivalent booster dose of the Pfizer-BioNTech COVID-19 vaccine among Veterans Health Administration (VHA) enrollees.</div></div><div><h3>Methods</h3><div>Repeated longitudinal, cohort study analyses using data from the VHA Corporate Data Warehouse were conducted. Among individuals who received ≥1 Pfizer-BioNTech COVID-19 vaccination between 12/11/2020–06/30/2023, an active comparator design was used to monitor the occurrence of 48 safety events of interest in this population compared to individuals with seasonal influenza vaccines during the 2014/2015–2018/2019 influenza seasons. In addition, a self-controlled risk interval design was used to compare the occurrence of safety events of interest during post-vaccination risk versus control intervals among individuals experiencing the safety event of interest.</div></div><div><h3>Results</h3><div>The Pfizer-BioNTech COVID-19 vaccine sample comprised 1,652,514 individuals, the majority of whom were male (89.8%) with an average age of 64.0 years (median = 67.4); it included 59.7% White non-Hispanic and 22.0% Black individuals. The seasonal influenza vaccine sample included 4,104,220 individuals, and baseline demographic and clinical characteristics were generally similar between the Pfizer-BioNTech COVID-19 and seasonal influenza vaccine samples (standardized differences &lt;10%). After signal detection analyses, further investigation was warranted for cerebrovascular non hemorrhagic stroke, other acute demyelinating disease, Guillain-Barré syndrome, anaphylaxis, acute myocardial infarction, arrhythmia, coronary artery disease, myocarditis, stress cardiomyopathy, microangiopathy, chilblain-like lesions, hemorrhagic disease, pulmonary embolism, optic neuritis, heart failure and cardiogenic shock, acute kidney injury, deep vein thrombosis, and severe COVID-19 disease. However, no safety events remained after signal evaluation analysis (including for myocarditis/pericarditis), regardless of the vaccine dose.</div></div><div><h3>Conclusions</h3><div>There was no increased risk of any of the 48 safety events of interest evaluated following Pfizer-BioNTech COVID-19 vaccination in the VHA population.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"29 ","pages":"Article 100791"},"PeriodicalIF":2.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146079247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IPV introduction in the routine vaccination programme in 2016 and subsequent shortage: a natural experiment in Guinea-Bissau","authors":"Line Møller Nanque ,&nbsp;Mario Careme ,&nbsp;Queba Djana ,&nbsp;Julie Odgaard Vedel ,&nbsp;Peter Aaby ,&nbsp;Ane Bærent Fisker","doi":"10.1016/j.jvacx.2026.100795","DOIUrl":"10.1016/j.jvacx.2026.100795","url":null,"abstract":"<div><h3>Background</h3><div>As part of the global polio eradication strategy, oral polio vaccine (OPV) will be replaced by the inactivated polio vaccine (IPV). Despite protection against polio, studies suggest that IPV may negatively affect child health, particularly for females.</div></div><div><h3>Methods</h3><div>In 2016, IPV was introduced to be co-administered with the third OPV (OPV3), and third pentavalent (diphtheria-tetanus-pertussis-haemophilus influenzae type B-hepatitis B) vaccine (penta3) at age 3.5 months. In a natural experiment arising from IPV introduction, shortage, and subsequent re-introduction, we compare the risk of outpatient non-accidental consultation, hospital admission and mortality after vaccination with penta3 + OPV3 + IPV versus penta3 + OPV3 in urban Guinea-Bissau. Children aged 3–8 months were followed from vaccination to first event. Adjusted hazard ratios (aHR) were estimated with 95% confidence intervals (CI) in Cox-proportional hazards models, overall and by sex.</div></div><div><h3>Results</h3><div>Among 5917 children vaccinated from August 2015–July 2019 (penta3 + OPV3 + IPV: 2083; penta3 + OPV3: 3834), we observed 2789 first consultations during 1371 person-years (PYRS), 92 hospital admissions during 1960 PYRS and 17 deaths during 1976 PYRS. Penta3 + OPV3 + IPV was not associated with increased risk of consultation overall (aHR 0.97, 95%CI 0.89–1.06) or among females (aHR 0.89, 95%CI 0.79–1.00). Nor did the risk of admission increase overall (aHR 0.88, 95%CI 0.56–1.37) or among females (aHR 0.69, 95%CI 0.35–1.35). Overall mortality tended to be lower among children receiving IPV (aHR 0.47, 95%CI 0.15–1.48). Yet, regardless of IPV, female mortality was higher than male mortality, the sex-difference being accentuated after IPV introduction (<em>p</em> = 0.003).</div></div><div><h3>Conclusions</h3><div>The risks of consultation, hospital admission and mortality were not increased after penta3 + OPV3 + IPV.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"29 ","pages":"Article 100795"},"PeriodicalIF":2.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147421633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world estimation of the pneumococcal vaccination coverage among high-risk population in the unified health system in Brazil: an administrative database analysis","authors":"Daniela V. Pachito ,&nbsp;Paulo H.R.F. Almeida ,&nbsp;Ricardo Macarini Ferreira ,&nbsp;Rodrigo F. Alexandre ,&nbsp;Ana Paula N. Burian","doi":"10.1016/j.jvacx.2026.100780","DOIUrl":"10.1016/j.jvacx.2026.100780","url":null,"abstract":"<div><h3>Background</h3><div>Immunization against pneumococcal disease (PD) for individuals with certain coexisting health conditions is recommended by the National Immunization Program (NIP) in the Unified Health System (SUS) in Brazil. There are uncertainties regarding the size of the population at risk and the proportion of high-risk individuals assessed at the Reference Centers for Special Immunobiologicals (<em>Centros de Referência para Imunobiológicos Especiais</em>, CRIE). Objectives were to assess the high-risk population size from a claims database, to estimate the vaccination coverage rate, and to assess the proportion of complete, incomplete and non-conforming vaccination schemes.</div></div><div><h3>Methods</h3><div>ICD-10 and procedure codes related to high-risk health conditions were defined, together with proxies of disease activity and severity. Data from the outpatient information system of medium-to-high complexity levels of care, and the information system of immunobiologicals were analyzed. Encrypted identifiers were used to count distinct individuals from November 2021 to October 2023. Complete vaccination scheme was defined as at least one PCV13 and two or more PPS23 doses; incomplete vaccination scheme as one PCV13 and less than two PPS23 doses; and non-conform vaccination scheme as more than one PCV13 and less than two PPS23 doses.</div></div><div><h3>Results</h3><div>The estimated size of the high-risk population was 1,609,181 individuals. Coverage rate for having received at least one dose of PCV13 was estimated at 45.5 % and for the complete vaccination scheme at 3.5 %. Most vaccination schemes were incomplete or non-conform.</div></div><div><h3>Conclusion</h3><div>A small proportion of high-risk individuals were considered as having received the complete pneumococcal vaccination scheme, possibly due to issues such as the high complexity of the vaccination scheme, and limited access to CRIE, due to the continental size of Brazil and the concentration of CRIE in large cities. These findings should be interpreted with caution, considering the inherent limitations of the data sources used.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"28 ","pages":"Article 100780"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145925825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress in the prevention of group B Streptococcus","authors":"Shuang Gao,&nbsp;Xiaona Wang,&nbsp;Xiaojuan Sun,&nbsp;Kangyi Li","doi":"10.1016/j.jvacx.2025.100761","DOIUrl":"10.1016/j.jvacx.2025.100761","url":null,"abstract":"<div><div>Group B <em>Streptococcus</em> (GBS) is a significant bacterial pathogen that poses substantial health risks, particularly among neonates and pregnant women. It is responsible for a range of severe infections, including sepsis, pneumonia, and meningitis, which can lead to high morbidity and mortality rates in these vulnerable populations. Therefore, the prevention of GBS and the implementation of necessary measures to prevent its progression to invasive GBS disease are of critical importance. Prior to the introduction of vaccines, intrapartum antibiotic prophylaxis (IAP) was considered the primary preventive strategy, as it effectively reduced the incidence of early-onset GBS (EOGBS) infection, defined as infection occurring within the first seven days of life. Moreover, it has notable limitations. The IAP is not only ineffective in preventing late-onset GBS (LOGBS, manifesting between the eighth day and the first three months of life) infections but also unlikely to prevent neonatal infections associated with stillbirth, preterm birth, or the early postnatal period. The widespread use of IAP may not only contribute to the emergence of antibiotic resistance due to excessive antibiotic exposure, but also exert detrimental effects on the neonatal microbiome. The development of effective GBS vaccines has therefore become a critical priority in modern medicine. This review delves into the intricate and multifaceted nature of GBS vaccines, beginning with an exploration of their antigenic targets. Antigens are fundamental components of vaccines because they stimulate the immune system to recognize and combat pathogens such as bacteria. In the case of GBS, several promising antigens have been identified, including capsular polysaccharides (CPS) and surface proteins. Among these, CPS stand out due to their critical role in enabling the bacterium to evade the host immune response. The article reviews the typical representatives of polysaccharide conjugate vaccines (the 6-valent GBS polysaccharide conjugate vaccine (GBS6)), the CPS-protein conjugate vaccine (semisynthetic carbohydrate-based vaccines), and protein-based vaccines (GBS-NN vaccine). Moreover, the article evaluates the potential impact of GBS vaccines on reducing disease burden. The ultimate objective is to support ongoing efforts in vaccine development aimed at mitigating associated health risks.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"28 ","pages":"Article 100761"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145737723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccination timeliness is a key measure of immunisation system performance: A call to address priority research, policy and practice issues","authors":"Oghenebrume Wariri ,&nbsp;Oumnia Bouaddi ,&nbsp;Jonathan F. Mosser ,&nbsp;Chigozie Edson Utazi ,&nbsp;Andrew Clark ,&nbsp;Beate Kampmann","doi":"10.1016/j.jvacx.2025.100762","DOIUrl":"10.1016/j.jvacx.2025.100762","url":null,"abstract":"","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"28 ","pages":"Article 100762"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145685294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of vaccination justifications on compliance and social polarization: A repeated cross-sectional study in eight countries","authors":"Tomoyuki Kobayashi ,&nbsp;Michio Murakami ,&nbsp;Asako Miura","doi":"10.1016/j.jvacx.2025.100766","DOIUrl":"10.1016/j.jvacx.2025.100766","url":null,"abstract":"<div><div>Risk communication recommending infection prevention actions could encourage compliance but may intensify conflicts of opinion toward infection prevention actions. This study addressed five reasons that justify vaccination in COVID-19 and examined their impact on compliance intent and opinions as well as on bias in intergroup attitudes based on differences in opinions toward vaccination. The study was designed as four repeated cross-sectional online surveys covering eight countries (Japan, the United Kingdom, the United States, China, Korea, Germany, Italy, and South Africa). The survey periods covered July and October 2023 and January and April 2024 (post-pandemic). A modified Poisson regression analysis was conducted on the effect of justifications on compliance intent, and a multiple regression analysis was conducted on the impact of justifications on the opinions tendency. In addition, multiple regression analysis was conducted on the effect of justifications on intergroup bias based on disagreement, focusing on the vaccine-accepting group. The results showed that justifications for vaccination, such as preventing harm to others, self-protection, reducing the number of infections and deaths in society, and social norms, have ambivalent effects; they tend to promote compliance intent and opinions tendency while worsening attitudes toward those with different opinions about vaccination. However, the justifications because of penalties was confirmed to reduce negative attitudes toward those with different opinions, while not promoting compliance intent or opinions tendency toward vaccination. When risk communication using infection protection and social norm perspectives is conducted, it is important to simultaneously design and advocate interventions to mitigate intergroup conflicts based on opinions toward infection prevention actions.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"28 ","pages":"Article 100766"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145737722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AderVax: Factors related to the acceptance or rejection of the COVID-19 vaccine in 8 cities in Colombia for the development of an intervention","authors":"Laura Juliana Valderrama-Orbegozo ,&nbsp;Laura Julieth Ramírez-Lasprilla ,&nbsp;Diana Estefanny Arce-Leonel ,&nbsp;Michell Rezene Tesfamariam-Ortega ,&nbsp;David Javier Fortich-Pérez","doi":"10.1016/j.jvacx.2025.100767","DOIUrl":"10.1016/j.jvacx.2025.100767","url":null,"abstract":"<div><div>Since the pandemic began, the COVID-19 vaccination has faced various challenges, including population hesitancy; these can be explained due to multiple factors that require further exploration. This study analyzes factors associated with either the acceptance or rejection of the COVID-19 vaccine as well as the intention to initiate or to complete vaccination schedules in individuals over the age of 18; individuals from eight cities in Colombia. The study encompasses both urban and rural areas, seeking to develop an intervention strategy. A total of 3384 individuals participated in a mixed-methods study which applied the DESVAAC scale and involved focus groups. Results show that only 11.3% of participants were highly motivated, intending to start or to continue vaccination. The health factor was significantly associated with greater intention (<em>p</em> &lt; 0.01) as compared to social or vaccine-related factors. Greater likelihood of vaccination was also associated with higher education (<em>p</em> &lt; 0.01), greater age (<em>p</em> &lt; 0.02), living with people with chronic conditions (<em>p</em> &lt; 0.05), or cohabiting with individuals over 50 years of age (<em>p</em> &lt; 0.028). Family support (82.9%) and observing others vaccinate (74.1%) were key motivators. Paucity of knowledge regarding vaccines was identified as an important factor, while decisions were also influenced by social, family, and health factors. Also, within the context of a pandemic, there were certain mandatory requirements. The study highlights that community leaders, media and cultural aspects significantly influenced the decision to get vaccinated. It is considered essential to strengthen coordinated efforts between government entities, social leaders, and the community; promoting increased training and education in order to support informed decision-making regarding vaccination within the context of social responsibility. Finally, the psychoeducational intervention strategy VACtívate was designed and implemented; targeting healthcare personnel, social leaders, and health authorities in order to better promote informed vaccination.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"28 ","pages":"Article 100767"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145790469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}